https://www.acticor-biotech.com https://www.acticor-biotech.com/company/about-us https://www.acticor-biotech.com/company/team https://www.acticor-biotech.com/company/board-of-directors https://www.acticor-biotech.com/company/partners https://www.acticor-biotech.com/company/prizes https://www.acticor-biotech.com/our-product/our-product-glenzocimab https://www.acticor-biotech.com/our-product/gpvi-glenzocimab-in-brief https://www.acticor-biotech.com/our-product/glenzocimab-in-acute-ischemic-stroke https://www.acticor-biotech.com/our-product/glenzocimab-in-stemi https://www.acticor-biotech.com/our-product/glenzocimab-in-other-indications https://www.acticor-biotech.com/pipeline https://www.acticor-biotech.com/about-stroke/about-stroke https://www.acticor-biotech.com/press-releases https://www.acticor-biotech.com/publications https://www.acticor-biotech.com/media-coverage https://www.acticor-biotech.com/events https://www.acticor-biotech.com/investors/investors-home https://www.acticor-biotech.com/investors/corporate-presentation https://www.acticor-biotech.com/investors/share-overview https://www.acticor-biotech.com/investors/regulated-information-2/shareholders-meeting https://www.acticor-biotech.com/investors/regulated-information-2/regulated-information https://www.acticor-biotech.com/investors/financial-agenda https://www.acticor-biotech.com/investors/contact https://www.acticor-biotech.com/about-stroke/stroke-key-figures https://www.acticor-biotech.com/contact-acticor-biotech https://www.acticor-biotech.com/legal-mentions https://www.acticor-biotech.com/about-stroke/what-is-a-stroke https://www.acticor-biotech.com/our-product/actimis-study-positive-results https://www.acticor-biotech.com/articles-category/press-release https://www.acticor-biotech.com/articles-category/publications https://www.acticor-biotech.com/articles-category/media-coverage https://www.acticor-biotech.com/articles-category/events https://www.acticor-biotech.com/investors/regulated-information-2/other-regulated-information https://www.acticor-biotech.com/investors/regulated-information-2/governance https://www.acticor-biotech.com/investors/ask-us-your-question https://www.acticor-biotech.com/investors/subscribe-to-email-alert https://www.acticor-biotech.com/careers https://www.acticor-biotech.com/posts/acticor-biotech-obtains-prime-status-from-the-european-medicines-agency-for-glenzocimab-in-the-treatment-of-stroke https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-issuance-of-a-patent-in-europe-for-glenzocimab-its-innovative-product-for-the-treatment-of-cardiovascular-emergencies https://www.acticor-biotech.com/posts/presentation-of-positive-results-from-the-actimis-phase-1b-2a-study-in-stroke-at-esoc-2022 https://www.acticor-biotech.com/posts/availability-of-the-2021-universal-registration-document-and-the-preparatory-documents-for-the-combined-general-meeting-of-may-12-2022 https://www.acticor-biotech.com/posts/2021-full-year-financial-results-and-update-on-clinical-development https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-appointment-of-corinne-le-goff-to-the-board-of-directors-as-an-independent-director https://www.acticor-biotech.com/posts/acticor-biotech-announces-positive-results-from-its-actimis-phase-1b-2a-study-in-patients-with-acute-ischemic-stroke-ais https://www.acticor-biotech.com/posts/results-of-the-phase-2-garden-study-in-covid-19-related-acute-respiratory-distress-syndrome-and-exclusive-interview-with-acticor-biotech-management https://www.acticor-biotech.com/posts/acticor-biotech-announces-coverage-of-its-stock-by-gilbert-dupont-and-kepler-cheuvreux https://www.acticor-biotech.com/posts/acticor-biotech-announces-fda-acceptance-of-ind-application-for-glenzocimab-in-acute-ischemic-stroke https://www.acticor-biotech.com/articles-category/press-release/b460e1fd_page-2 https://www.acticor-biotech.com/posts/targeting-platelet-gpvi-with-glenzocimab-a-novel-mechanism-for-inhibition-blood-advances https://www.acticor-biotech.com/posts/glenzocimab-does-not-impact-glycoprotein-vi-dependent-inflammatory-haemostasis https://www.acticor-biotech.com/posts/pharmacological-blockade-of-glycoprotein-vi-promotes-thrombus-disaggregation-in-the-absence-of-thrombin https://www.acticor-biotech.com/posts/population-pharmacokinetic-pharmacodynamic-modeling-of-glenzocimab-act017-a-glycoprotein-vi-inhibitor-of-collagen-induced-platelet-aggregation https://www.acticor-biotech.com/posts/acute-ischemic-stroke-thrombi-have-an-outer-shell-that-impairs-fibrinolysis https://www.acticor-biotech.com/posts/safety-and-tolerability-pharmacokinetics-and-pharmacodynamics-of-act017-an-antiplatelet-gpvi-glycoprotein-vi-fab https://www.acticor-biotech.com/posts/quality-and-cost-assessment-of-a-recombinant-antibody-fragment-produced-from-mammalian-yeast-and-prokaryotic-host-cells-a-case-study-prior-to-pharmaceutical-development https://www.acticor-biotech.com/posts/immobilized-fibrinogen-activates-human-platelets-through-glycoprotein-vi https://www.acticor-biotech.com/posts/design-development-and-characterization-of-act017-a-humanized-fab-that-blocks-platelets-glycoprotein-vi-function-without-causing-bleeding-risks https://www.acticor-biotech.com/posts/international-journal-of-stroke-beyond-antiplatelets-the-role-of-glycoprotein-vi-in-ischemic-stroke https://www.acticor-biotech.com/articles-category/publications/b460e1fd_page-2 https://www.acticor-biotech.com/posts/interview-de-franck-mouthon-president-de-france-biotech-sur-les-societes-de-sante-ayant-integre-la-french-tech-120-sur-bfm-business https://www.acticor-biotech.com/posts/les-echos-7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/posts/capitalfinance-acticor-biotech-porte-sa-serie-b-a-22-3-meu https://www.acticor-biotech.com/posts/acticor-releve-7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/posts/biotech-info-acticor-biotech-partenaire-du-consortium-booster-dedie-a-la-prise-en-charge-et-aux-nouveaux-traitements-des-avc https://www.acticor-biotech.com/posts/act017-un-fragment-danticorps-dont-laction-antithrombotique-est-prometteuse https://www.acticor-biotech.com/posts/cardiovascularbusiness-novel-antiplatelet-could-circumvent-bleeding-risk-for-stroke-patients https://www.acticor-biotech.com/posts/cardiologyconsultant-novel-antiplatelet-may-offer-antithrombotic-effect-without-bleeding-risk https://www.acticor-biotech.com/posts/penn-state-health-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/posts/american-heart-association-new-drug-to-prevent-clots-clears-safety-hurdle-2 https://www.acticor-biotech.com/posts/wsc-2023-meet-acticor-biotech-at-the-15th-world-stroke-congress-in-toronto-canada https://www.acticor-biotech.com/posts/esc-2023-meet-acticor-biotech-at-the-next-esc-conference-in-amsterdam-netherlands https://www.acticor-biotech.com/posts/bio-2023-meet-acticor-biotech-at-the-next-bio-conference-in-boston-united-states https://www.acticor-biotech.com/posts/esoc-2023-meet-acticor-biotech-at-the-next-european-stroke-conference-in-munich-germany https://www.acticor-biotech.com/posts/bio-equity-2023-meet-acticor-biotech-at-the-next-bio-equity-in-dublin-ireland https://www.acticor-biotech.com/posts/wlnc-2023-meet-acticor-biotech-at-the-next-wlnc-conference-in-rio-brasil https://www.acticor-biotech.com/posts/dia-europe-2023-meet-acticor-biotech-at-the-next-dia-europe-in-basel-switzerland https://www.acticor-biotech.com/posts/bio-spring-2023-meet-acticor-biotech-at-the-next-bio-spring-conference-in-basel-switzerland https://www.acticor-biotech.com/posts/isc-2023-meet-acticor-biotech-at-the-next-international-stroke-conference-in-dallas-united-states https://www.acticor-biotech.com/posts/meet-acticor-biotech-at-the-next-biotech-showcase-conference-in-san-francisco https://www.acticor-biotech.com/articles-category/events/b460e1fd_page-2 https://www.acticor-biotech.com/posts/acticor-biotech-is-the-laureate-of-the-prix-galien-medstartup-award-in-the-category-best-collaboration-in-the-pharmaceutical-or-biotechnology-industry https://www.acticor-biotech.com/posts/success-of-acticor-biotechs-initial-public-offering-on-the-euronext-growth-r-market-with-eu15-5-million-raised https://www.acticor-biotech.com/posts/acticor-biotech-launches-its-initial-public-offering-on-the-euronext-growth-r-market-in-paris https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-first-patient-in-actisave-its-adaptive-phase-2-3-efficacy-study-in-acute-ischemic-stroke https://www.acticor-biotech.com/posts/acticor-biotech-announces-its-projected-ipo-on-the-euronext-growth-r-market-in-paris https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-completion-of-enrollment-in-its-garden-clinical-trial-a-covid-19-induced-acute-respiratory-distress-syndrome-efficacy-study https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-completion-of-enrollment-in-actimis-its-key-phase-1b-2a-safety-study https://www.acticor-biotech.com/posts/acticor-biotech-announces-appointment-of-mr-alain-munoz-as-chairman-of-the-board-of-directors-and-mrs-sophie-binay-and-mr-yannick-pletan-as-general-managers https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-recruitment-of-the-first-patient-in-its-phase-2-garden-study-in-covid-19-related-ards https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-success-of-the-first-phase-of-its-actimis-study-with-glenzocimab-in-patients-with-acute-ischemic-stroke https://www.acticor-biotech.com/articles-category/press-release/b460e1fd_page-1 https://www.acticor-biotech.com/articles-category/press-release/b460e1fd_page-3 https://www.acticor-biotech.com/posts/journal-of-thrombosis-and-haemostasis-antiplatelet-drugs-which-targets-for-which-treatments https://www.acticor-biotech.com/posts/blood-journal-platelet-glycoprotein-vi-binds-to-polymerized-fibrin-and-promotes-thrombin-generation https://www.acticor-biotech.com/posts/jpet-a-humanized-glycoprotein-vi-gpvi-mouse-model-to-assess-the-antithrombotic-efficacies-of-anti-gpvi-agents https://www.acticor-biotech.com/posts/platelets-drive-thrombus-propagation-in-a-hematocrit-and-glycoprotein-vi-dependent-manner-in-an-in-vitro-venous-thrombosis-model https://www.acticor-biotech.com/posts/svin-meeting https://www.acticor-biotech.com/posts/sfnv-22 https://www.acticor-biotech.com/posts/wsc-22 https://www.acticor-biotech.com/posts/bio-europe-leipzig-oct-24-26-2022-meet-acticor-biotech-at-bio-europe-in-leipzig https://www.acticor-biotech.com/posts/midcap-event-paris https://www.acticor-biotech.com/posts/investor-access-oct-6-7-2022-meet-acticor-biotech-at-the-next-investor-access https://www.acticor-biotech.com/posts/isfp-2022 https://www.acticor-biotech.com/posts/isth-2022 https://www.acticor-biotech.com/posts/spring-midcap-event-paris https://www.acticor-biotech.com/posts/bio-san-diego https://www.acticor-biotech.com/articles-category/events/b460e1fd_page-1 https://www.acticor-biotech.com/articles-category/events/b460e1fd_page-3 https://www.acticor-biotech.com/posts/acticor-biotech-integre-le-1-er-french-tech-120 https://www.acticor-biotech.com/posts/acticor-biotech-raises-eu7m-in-addition-to-its-series-b-financing-now-completed-at-eu22-3m https://www.acticor-biotech.com/posts/acticor-biotech-partner-of-the-booster-consortium-dedicated-to-management-and-new-treatments-of-stroke-in-emergency-situations https://www.acticor-biotech.com/posts/a-60meu-regional-development-and-commercialisation-agreement-signed-with-china-medical-system-holding-limited-r https://www.acticor-biotech.com/posts/acticor-biotech-confirms-simbec-orion-to-make-its-first-in-patient-study-in-acute-ischemic-stroke https://www.acticor-biotech.com/posts/acticor-biotech-announces-that-the-european-medicines-agency-clears-the-route-for-a-phase-ii-of-its-act017-product-in-stroke https://www.acticor-biotech.com/posts/acticor-biotech-completed-its-phase-i-clinical-trial-with-act017-achieving-its-safety-and-tolerability-primary-endpoints https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-closing-of-a-eu1-7-million-equity-financing-led-by-primer-capital https://www.acticor-biotech.com/posts/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer https://www.acticor-biotech.com/posts/acticor-biotech-first-in-human-clinical-trial-in-healthy-volunteers https://www.acticor-biotech.com/articles-category/press-release/b460e1fd_page-4 https://www.acticor-biotech.com/posts/bio-equity-meet-acticor-biotech-at-bio-equity-in-milan https://www.acticor-biotech.com/posts/esoc22-meet-acticor-biotech-at-the-8th-european-stroke-organisation-conference https://www.acticor-biotech.com/posts/small-cap-event-meet-acticor-biotech-at-the-small-cap-event-in-paris https://www.acticor-biotech.com/posts/bio-europe-spring-2022-meet-acticor-biotech-at-bio-europe-spring-in-basel https://www.acticor-biotech.com/posts/medintechs-come-meet-acticor-biotech-at-the-medintechs-event-in-paris https://www.acticor-biotech.com/posts/webinar-presenting-positive-results-from-its-phase-1b-2a-study-actimis-in-patients-with-ischemic-stroke https://www.acticor-biotech.com/posts/isc-2022 https://www.acticor-biotech.com/posts/meet-acticor-biotech-at-biotech-show-case-san-fransico-usa https://www.acticor-biotech.com/posts/acticor-biotech-wishes-you-a-happy-new-year-2 https://www.acticor-biotech.com/posts/meet-acticor-biotech-at-biofit-conference https://www.acticor-biotech.com/articles-category/events/b460e1fd_page-4 https://www.acticor-biotech.com/posts/acticor-reached-the-milestones-triggering-the-second-payment-in-the-research-agreement-with-its-pharma-partner-mediolanum https://www.acticor-biotech.com/posts/acticor-biotech-has-selected-its-contract-research-organisation-to-manage-clinical-study-phase-i https://www.acticor-biotech.com/posts/investir-day-meet-acticor-biotech-at-investir-day-forum-palais-brongniart-paris https://www.acticor-biotech.com/posts/sfnv-meet-acticor-biotech-at-the-26th-societe-francaise-de-neuro-vasculaire-days https://www.acticor-biotech.com/posts/svin-meet-acticor-biotech-at-the-society-of-vascular-and-interventional-neurology-annual-meeting-phoenix-usa https://www.acticor-biotech.com/posts/world-stroke-day-2021 https://www.acticor-biotech.com/posts/acticor-biotech-is-nominated-for-the-8th-edition-of-the-galien-medstartup-awards-october-27-28-2021-in-new-york-city https://www.acticor-biotech.com/posts/meet-us-at-biotech-showcase-san-fransisco-ca-jan-13-15-202 https://www.acticor-biotech.com/posts/paris-biotech-sante https://www.acticor-biotech.com/posts/acticor-biotech-wishes-you-a-happy-new-year https://www.acticor-biotech.com/posts/24emes-journees-de-la-societe-francaise-neuro-vasculaire https://www.acticor-biotech.com/posts/meet-us-at-bio-europe-2019 https://www.acticor-biotech.com/articles-category/events/b460e1fd_page-5 https://www.acticor-biotech.com/10-me-cest-le-montant-de-la-levee-de-fonds-pour-acticor-biotech-biotech-finances-fr https://www.acticor-biotech.com/2020-wishes https://www.acticor-biotech.com/24emes-journees-de-la-societe-francaise-neuro-vasculaire https://www.acticor-biotech.com/7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/no_redirect-true https://www.acticor-biotech.com/s-{search_term} https://www.acticor-biotech.com/a-60me-regional-development-and-commercialisation-agreement-signed-with-china-medical-system-holding-limited https://www.acticor-biotech.com/about-us https://www.acticor-biotech.com/about-us/board-of-directors https://www.acticor-biotech.com/about-us/company-overview https://www.acticor-biotech.com/about-us/executive-team https://www.acticor-biotech.com/about-us/project-team https://www.acticor-biotech.com/about-us/scientific-founders https://www.acticor-biotech.com/act017-un-fragment-danticorps-dont-laction-antithrombotique-est-prometteuse https://www.acticor-biotech.com/acticor-15-me-pour-devenir-premier-de-la-classe-biotech-finances-fr https://www.acticor-biotech.com/acticor-biotech-a-key-rd-deal-after-a-successful-funding-round https://www.acticor-biotech.com/acticor-biotech-a-recu-le-prix-de-linnovation-2017-caduresco-fr https://www.acticor-biotech.com/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-avec-son-candidat-act017-industrie-mag-fr https://www.acticor-biotech.com/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-biotech-finance-fr https://www.acticor-biotech.com/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer https://www.acticor-biotech.com/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer-biotech-finances https://www.acticor-biotech.com/acticor-biotech-announces-appointment-of-mr-alain-munoz-as-chairman-of-the-board-of-directors-and-mrs-sophie-binay-and-mr-yannick-pletan-as-general-managers https://www.acticor-biotech.com/acticor-biotech-announces-that-the-european-medicines-agency-clears-the-route-for-a-phase-ii-of-its-act017-product-in-stroke https://www.acticor-biotech.com/acticor-biotech-announces-the-closing-of-a-e17-million-equity-financing-led-by-primer-capital https://www.acticor-biotech.com/acticor-biotech-announces-the-completion-of-enrollment-in-actimis-its-key-phase-1b-2a-safety-study https://www.acticor-biotech.com/acticor-biotech-announces-the-recruitment-of-the-first-patient-in-its-phase-2-garden-study-in-covid-19_related-ards https://www.acticor-biotech.com/acticor-biotech-announces-the-success-of-the-first-phase-of-its-actimis-study-with-glenzocimab-in-patients-with-acute-ischemic-stroke https://www.acticor-biotech.com/acticor-biotech-bets-on-crowdfunding-for-health-and-successfully-raises-its-first-seed-round https://www.acticor-biotech.com/acticor-biotech-completed-its-phase-i-clinical-trial-with-act017-achieving-its-safety-and-tolerability-primary-endpoints https://www.acticor-biotech.com/acticor-biotech-confirms-simbec-orion-to-make-its-first-in-patient-study-in-acute-ischemic-stroke https://www.acticor-biotech.com/acticor-biotech-featured-in-usine-nouvelle-magazine-n3396 https://www.acticor-biotech.com/acticor-biotech-first-in-human-clinical-trial-in-healthy-volunteers https://www.acticor-biotech.com/acticor-biotech-has-selected-its-contract-research-organisation-to-manage-clinical-study-phase-i https://www.acticor-biotech.com/acticor-biotech-in-les-echos-journal https://www.acticor-biotech.com/acticor-biotech-in-science-sante-magazine https://www.acticor-biotech.com/acticor-biotech-integre-le-1-er-french-tech-120 https://www.acticor-biotech.com/acticor-biotech-internationalise-son-tour-de-table-les-echos-fr https://www.acticor-biotech.com/acticor-biotech-on-biotech-info https://www.acticor-biotech.com/acticor-biotech-partenaire-du-consortium-booster-dedie-a-la-prise-en-charge-et-aux-nouveaux-traitements-des-avc https://www.acticor-biotech.com/acticor-biotech-partner-of-the-booster-consortium-dedicated-to-management-and-new-treatments-of-stroke-in-emergency-situations https://www.acticor-biotech.com/acticor-biotech-porte-sa-serie-b-a-223-me https://www.acticor-biotech.com/acticor-biotech-raises-e15-3m-in-a-series-b-financing https://www.acticor-biotech.com/acticor-biotech-raises-e7m-in-addition-to-its-series-b-financing-now-completed-at-e223m https://www.acticor-biotech.com/acticor-biotech-realise-une-augmentation-de-capital-de-17me-biotech-info-fr https://www.acticor-biotech.com/acticor-biotech-recoit-la-deuxieme-partie-du-financement-de-mediolanum-biotechinfo-fr https://www.acticor-biotech.com/acticor-biotech-retient-simbec-orion-pour-une-etude-clinique-actulabo-fr https://www.acticor-biotech.com/acticor-biotech-se-renforce-cf-news-fr https://www.acticor-biotech.com/acticor-biotech-secures-e15m-new-funding-from-capdecisif-management https://www.acticor-biotech.com/acticor-biotech-selects-catalent-gpex-cell-line-development-technology-to-develop-act-017 https://www.acticor-biotech.com/acticor-biotech-signe-en-chine-un-contrat-de-licence-de-plus-de-60-m-eur-afp-fr https://www.acticor-biotech.com/acticor-biotech-signe-en-chine-un-contrat-de-plus-de-60m-eur-le-figaro-fr https://www.acticor-biotech.com/acticor-biotech-starts-a-crowdfunding-campaign https://www.acticor-biotech.com/acticor-biotech-veut-faire-passer-un-cap-a-la-lutte-contre-lavc-decideurs-magazine-fr https://www.acticor-biotech.com/acticor-reached-the-milestones-triggering-the-second-payment-in-the-research-agreement-with-its-pharma-partner-mediolanum https://www.acticor-biotech.com/acticor-releve-7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/acticors-blood-thinner-cuts-hemorrhage-risk-in-human-study-could-offer-hope-for-acute-stroke https://www.acticor-biotech.com/acute-ischemic-stroke-thrombi-have-an-outer-shell-that-impairs-fibrinolysis https://www.acticor-biotech.com/articles-category/events_b460e1fd_page-1 https://www.acticor-biotech.com/articles-category/events_b460e1fd_page-2 https://www.acticor-biotech.com/articles-category/events_b460e1fd_page-3 https://www.acticor-biotech.com/articles-category/events_b460e1fd_page-4 https://www.acticor-biotech.com/articles-category/events_b460e1fd_page-5 https://www.acticor-biotech.com/articles-category/media-coverage_b460e1fd_page-1 https://www.acticor-biotech.com/articles-category/media-coverage_b460e1fd_page-2 https://www.acticor-biotech.com/articles-category/media-coverage_b460e1fd_page-3 https://www.acticor-biotech.com/articles-category/media-coverage_b460e1fd_page-4 https://www.acticor-biotech.com/articles-category/media-coverage_b460e1fd_page-5 https://www.acticor-biotech.com/articles-category/press-release_b460e1fd_page-2 https://www.acticor-biotech.com/articles-category/press-release_b460e1fd_page-3 https://www.acticor-biotech.com/articles-category/press-release_b460e1fd_page-4 https://www.acticor-biotech.com/articles-category/publications_b460e1fd_page-2 https://www.acticor-biotech.com/avc-des-innovations-pour-gagner-quelques-precieuses-heures-lusine-nouvelle-fr https://www.acticor-biotech.com/avc-les-promesses-de-la-science-lexpress-fr https://www.acticor-biotech.com/avc-un-candidat-medicament-la-revue-du-practicien-fr https://www.acticor-biotech.com/biopharmanalyses-fr-acticor-biotech-selects-its-first-lead-compound https://www.acticor-biotech.com/biopharmanalyses-fr-french-crowdfunding-supports-acticor-biotech https://www.acticor-biotech.com/biotech-finances-acticor-biotech-collects-590ke-to-start-its-preclinical-development https://www.acticor-biotech.com/biotech-finances-acticor-moves-forward-and-comes-back-to-crowdfunding https://www.acticor-biotech.com/biotech-finances-twice-rewarded-acticor-to-raise-funds-again https://www.acticor-biotech.com/blog/2013/12/30/acticor-biotech-s-installe https://www.acticor-biotech.com/blog/2014/03/24/en-savoir-plus-avc https://www.acticor-biotech.com/blog/2014/04/22/acticor-biotech-signe-accord-licence-exclusive-mondiale-inserm-transfert-domaine-laccident-vasculaire-cerebral-avc https://www.acticor-biotech.com/blog/2014/05/20/acticor-biotech-demarre-campagne-crowdfunding https://www.acticor-biotech.com/blog/2014/06/20/rencontrez-lequipe-dacticor-biotech-1er-juillet-2014 https://www.acticor-biotech.com/blog/2014/07/25/acticor-biotech-biotech-info https://www.acticor-biotech.com/blog/2014/09/07/acticor-biotech-science-sante https://www.acticor-biotech.com/blog/2014/10/29/acticor-biotech-selectionne-lead https://www.acticor-biotech.com/blog/2014/11/17/acticor-biotech-journal-les-echos https://www.acticor-biotech.com/blog/2014/11/25/acticor-biotech-pepite-dusine-nouvelle-n3396 https://www.acticor-biotech.com/blog/2014/11/26/gilles-avenard-invite-conference-innover-investir-sante-angels-santebpi https://www.acticor-biotech.com/blog/2014/11/30/biopharmanalyses-acticor-biotech-selectionne-son-premier-lead https://www.acticor-biotech.com/blog/2015/01/26/acticor-biotech-mise-financement-participatif-reussit-levee-fond-damorçage https://www.acticor-biotech.com/blog/2015/02/01/labiotech-fr-acticor-biotech-reussi-le-pari-du-crowdfunding https://www.acticor-biotech.com/blog/2015/02/02/biotech-finances-acticor-biotech-collecte-590-ke-pour-son-entree-en-pre-clinique https://www.acticor-biotech.com/blog/2015/02/06/les-echos-crowdfunding-nouvelles-plates-formes-nouveaux-projets https://www.acticor-biotech.com/blog/2015/02/23/biopharmanalyses-le-crowdfunding-francais-soutient-acticor-biotech https://www.acticor-biotech.com/blog/2015/06/01/un-point-sur-lavc-avec-arte https://www.acticor-biotech.com/blog/2015/06/16/lettre-dinformation-actionnaires-juin-2015 https://www.acticor-biotech.com/blog/2015/06/23/acticor-biotech-dans-envoye-special-jeudi-25-juin-a-20h45 https://www.acticor-biotech.com/blog/2015/08/21/la-cible-gpvi-dans-le-journal-international-de-medecine-jim https://www.acticor-biotech.com/blog/2016/03/02/acticor-biotech-selects-catalent-gpex-cell-line-development-technology-to-develop-act-017 https://www.acticor-biotech.com/blog/2016/04/01/biotech-finances-acticor-avance-et-retourne-au-crowdfunding https://www.acticor-biotech.com/blog/2016/07/19/biotechfinances-double-laureate-acticor-leve-des-fonds https://www.acticor-biotech.com/blog/author/acticorwp_75 https://www.acticor-biotech.com/blog/author/adminacticor https://www.acticor-biotech.com/blog/author/antoinerev https://www.acticor-biotech.com/blog/category/news https://www.acticor-biotech.com/blog/category/presse https://www.acticor-biotech.com/blog/category/presse/communique https://www.acticor-biotech.com/blog/tag/gpvi https://www.acticor-biotech.com/blood-journal-platelet-glycoprotein-vi-binds-to-polymerized-fibrin-and-promotes-thrombin-generation https://www.acticor-biotech.com/category/events https://www.acticor-biotech.com/category/events/page/2 https://www.acticor-biotech.com/category/media-coverage https://www.acticor-biotech.com/category/media-coverage/page/10 https://www.acticor-biotech.com/category/media-coverage/page/11 https://www.acticor-biotech.com/category/media-coverage/page/12 https://www.acticor-biotech.com/category/media-coverage/page/2 https://www.acticor-biotech.com/category/media-coverage/page/3 https://www.acticor-biotech.com/category/media-coverage/page/4 https://www.acticor-biotech.com/category/media-coverage/page/5 https://www.acticor-biotech.com/category/media-coverage/page/6 https://www.acticor-biotech.com/category/media-coverage/page/7 https://www.acticor-biotech.com/category/media-coverage/page/8 https://www.acticor-biotech.com/category/media-coverage/page/9 https://www.acticor-biotech.com/category/press-releases https://www.acticor-biotech.com/category/press-releases/page/2 https://www.acticor-biotech.com/category/press-releases/page/3 https://www.acticor-biotech.com/category/press-releases/page/4 https://www.acticor-biotech.com/category/press-releases/page/5 https://www.acticor-biotech.com/category/publications https://www.acticor-biotech.com/category/publications/page/2 https://www.acticor-biotech.com/checkout https://www.acticor-biotech.com/checkout_locale https://www.acticor-biotech.com/contact https://www.acticor-biotech.com/credits https://www.acticor-biotech.com/design-development-and-characterization-of-act017-a-humanized-fab-that-blocks-platelets-glycoprotein-vi-function-without-causing-bleeding-risks https://www.acticor-biotech.com/e1-4-million-capital-increase-by-acticor-biotech https://www.acticor-biotech.com/en https://www.acticor-biotech.com/en/acticor-biotech-bets-crowdfunding-health-successfully-raises-first-seed-round https://www.acticor-biotech.com/en/acticor-biotech-selects-catalent-gpex-cell-line-development-technology-to-develop-act-017 https://www.acticor-biotech.com/en/biopharmanalyses-fr-acticor-biotech-selects-its-first-lead-compound https://www.acticor-biotech.com/en/biopharmanalyses-fr-french-crowdfunding-supports-acticor-biotech https://www.acticor-biotech.com/en/biotech-finances-acticor-biotech-collects-590ke-start-preclinical-development https://www.acticor-biotech.com/en/blood-journal-platelet-glycoprotein-vi-binds-to-polymerized-fibrin-and-promotes-thrombin-generation https://www.acticor-biotech.com/en/company https://www.acticor-biotech.com/en/contact https://www.acticor-biotech.com/en/fr-gilles-avenard-guest-innover-et-investir-dans-la-sante-angels-santebpi https://www.acticor-biotech.com/en/investors https://www.acticor-biotech.com/en/labiotech-eu-biotechs-crowdfunding-france-top-class https://www.acticor-biotech.com/en/labiotech-fr-acticor-biotech-wins-crowdfunding-bet https://www.acticor-biotech.com/en/les-echos-fr-crowdfunding-new-platforms-new-projects https://www.acticor-biotech.com/en/meet-acticor-biotech-team-paris-july-1st-2014 https://www.acticor-biotech.com/en/mentions-legales https://www.acticor-biotech.com/en/news-et-media https://www.acticor-biotech.com/en/shareholders-area https://www.acticor-biotech.com/en/stroke https://www.acticor-biotech.com/en/stroke/outcomes https://www.acticor-biotech.com/en/stroke/treatment https://www.acticor-biotech.com/en/team https://www.acticor-biotech.com/en/technology https://www.acticor-biotech.com/en/s-{search_term} https://www.acticor-biotech.com/espace-actionnaires https://www.acticor-biotech.com/experimental-antiplatelet-compound-for-acute-stroke-shows-promise https://www.acticor-biotech.com/experimental-antiplatelet-compound-for-acute-stroke-shows-promise-2 https://www.acticor-biotech.com/experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk-2 https://www.acticor-biotech.com/experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk-3 https://www.acticor-biotech.com/experimental-drug-can-prevent-strokes https://www.acticor-biotech.com/exports-pages https://www.acticor-biotech.com/fr-acticor-biotech-signe-un-accord-de-licence-exclusive-et-mondiale-avec-inserm-transfert-dans-le-domaine-de-laccident-vasculaire-cerebral-avc https://www.acticor-biotech.com/fr-acticor-biotech-sinstalle-a-lhopital-bichat-dans-lunite-inserm-u1148 https://www.acticor-biotech.com/gilles-avenard-guest-of-innover-et-investir-dans-la-sante-innovate-and-invest-in-health-conference https://www.acticor-biotech.com/gilles-avenard-recoit-le-prix-de-linnovation-2017-biotech-finances-fr https://www.acticor-biotech.com/gordon-research-conference-cell-biology-of-megakaryocytes-and-platelets https://www.acticor-biotech.com/homepage https://www.acticor-biotech.com/immobilized-fibrinogen-activates-human-platelets-through-glycoprotein-vi https://www.acticor-biotech.com/international-journal-of-stroke-beyond-antiplatelets-the-role-of-glycoprotein-vi-in-ischemic-stroke https://www.acticor-biotech.com/interview-de-franck-mouthon-president-de-france-biotech-sur-les-societes-de-sante-ayant-integre-la-french-tech-120-sur-bfm-business https://www.acticor-biotech.com/investisseurs https://www.acticor-biotech.com/investors/regulated-information-2/financial-information-2021 https://www.acticor-biotech.com/investors/regulated-information-2/financial-information-2022 https://www.acticor-biotech.com/investors/regulated-information-2/other-regulated-information-2021 https://www.acticor-biotech.com/investors/regulated-information-2/other-regulated-information-2023 https://www.acticor-biotech.com/ipo-event-rsvp https://www.acticor-biotech.com/isth-2019-congress https://www.acticor-biotech.com/isth-honors-five-members-with-esteemed-career-awards https://www.acticor-biotech.com/journal-of-thrombosis-and-haemostasis-antiplatelet-drugs-which-targets-for-which-treatments https://www.acticor-biotech.com/la-question-du-suivi-de-temperature-industrie-pharma-fr https://www.acticor-biotech.com/la-start-up-acticor-qui-developpe-un-traitement-contre-les-avc-a-boucle-une-levee-de-fonds-en-serie-b-de-153-millions-deuros-les-echos-fr https://www.acticor-biotech.com/labiotech-eu-biotechs-crowdfunding-is-france-top-of-the-class https://www.acticor-biotech.com/labiotech-fr-acticor-biotech-wins-its-crowdfunding-bet https://www.acticor-biotech.com/lancet-endovascular-thrombectomy-after-large-vessel-ischaemic-stroke-a-meta-analysis-of-individual-patient-data-from-five-randomised-trials https://www.acticor-biotech.com/lavc https://www.acticor-biotech.com/lavc/consequences https://www.acticor-biotech.com/lavc/traitement https://www.acticor-biotech.com/le-francais-acticor-biotech-signe-un-accord-de-developpement-en-chine-la-tribune-fr https://www.acticor-biotech.com/le-marche-pharma-mondial-vers-les-1-400-md-en-2020-actulabo-fr https://www.acticor-biotech.com/lentreprise https://www.acticor-biotech.com/lequipe https://www.acticor-biotech.com/les-echos-fr-crowdfunding-new-platforms-new-projects https://www.acticor-biotech.com/les-effets-secondaires-du-levothyrox-affectent-aussi-la-regulation-actulabo-fr https://www.acticor-biotech.com/les-entrepreneurs-de-la-healthtech-francaise-en-premiere-ligne-pour-lutter-contre-la-covid-19 https://www.acticor-biotech.com/mcdermott-accompagne-acticor-biotech-le-monde-du-droit-fr https://www.acticor-biotech.com/media-center https://www.acticor-biotech.com/meet-acticor-biotech-team-in-paris-on-july-1st-2014 https://www.acticor-biotech.com/meet-us-at-bioeurope2019 https://www.acticor-biotech.com/meet-us-at-biojapan-2019 https://www.acticor-biotech.com/meet-us-at-biotech-showcase https://www.acticor-biotech.com/mentions-legales https://www.acticor-biotech.com/new-antiplatelet-may-lower-bleeding-risk-in-stroke https://www.acticor-biotech.com/new-blood-thinner-may-prevent-stroke-without-risk-for-bleeding https://www.acticor-biotech.com/new-drug-to-prevent-clots-clears-safety-hurdle https://www.acticor-biotech.com/new-drug-to-prevent-clots-clears-safety-hurdle-2 https://www.acticor-biotech.com/news-et-media https://www.acticor-biotech.com/news-et-media/page/2 https://www.acticor-biotech.com/news-et-media/page/3 https://www.acticor-biotech.com/novel-antiplatelet-could-circumvent-bleeding-risk-for-stroke-patients https://www.acticor-biotech.com/novel-antiplatelet-may-offer-antithrombotic-effect-without-bleeding-risk https://www.acticor-biotech.com/order-confirmation https://www.acticor-biotech.com/parisbiotechsante https://www.acticor-biotech.com/partners-investors-new https://www.acticor-biotech.com/paypal-checkout https://www.acticor-biotech.com/pharmacie-la-chine-seveille-le-figaro-fr https://www.acticor-biotech.com/population-pharmacokinetic-pharmacodynamic-modeling-of-glenzocimab-act017-a-glycoprotein-vi-inhibitor-of-collagen-induced-platelet-aggregation https://www.acticor-biotech.com/posts/10-meu-cest-le-montant-de-la-levee-de-fonds-pour-acticor-biotech-biotech-finances-fr https://www.acticor-biotech.com/posts/acticor-15-meu-pour-devenir-premier-de-la-classe-biotech-finances-fr https://www.acticor-biotech.com/posts/acticor-adapts-its-actisave-clinical-study-to-prepare-the-registration-of-glenzocimab-for-the-treatment-of-stroke https://www.acticor-biotech.com/posts/acticor-biotech-a-recu-le-prix-de-linnovation-2017-caduresco-fr https://www.acticor-biotech.com/posts/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-avec-son-candidat-act017-industrie-mag-fr https://www.acticor-biotech.com/posts/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-biotech-finance-fr https://www.acticor-biotech.com/posts/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer-biotech-finances https://www.acticor-biotech.com/posts/acticor-biotech-announces-its-2022-half-year-financial-results-and-update-on-its-clinical-progress https://www.acticor-biotech.com/posts/acticor-biotech-announces-its-financial-agenda-for-the-1st-half-of-2023 https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-appointment-of-patricia-zilliox-to-the-board-of-directors-as-an-independent-director https://www.acticor-biotech.com/posts/acticor-biotech-announces-the-enrollment-of-the-first-us-patient-in-its-phase-2-3-study-actisave-for-the-treatment-of-stroke-press-release https://www.acticor-biotech.com/posts/acticor-biotech-augmenter-les-chances-de-survie-dans-lavc-investir-fr https://www.acticor-biotech.com/posts/acticor-biotech-internationalise-son-tour-de-table-les-echos-fr https://www.acticor-biotech.com/posts/acticor-biotech-introduction-en-bourse-et-levee-de-fonds-de-20meu-lancees https://www.acticor-biotech.com/posts/acticor-biotech-karista-the-rise-of-a-game-changer-to-fight-stroke https://www.acticor-biotech.com/posts/acticor-biotech-launches-a-capital-increase-for-an-amount-of-c-10-million-euros https://www.acticor-biotech.com/posts/acticor-biotech-postpones-release-of-its-2022-half-year-financial-results https://www.acticor-biotech.com/posts/acticor-biotech-progress-in-discussions-with-eu-and-us-regulatory-agencies https://www.acticor-biotech.com/posts/acticor-biotech-provides-an-update-on-the-us-regulatory-discussion-with-the-fda https://www.acticor-biotech.com/posts/acticor-biotech-publishes-its-2022-annual-results-and-provides-an-update-on-its-clinical-progress https://www.acticor-biotech.com/posts/acticor-biotech-realise-une-augmentation-de-capital-de-1-7meu-biotech-info-fr https://www.acticor-biotech.com/posts/acticor-biotech-receives-european-medicines-agency-ema-endorsement-on-key-parameters-of-actisave-its-pivotal-phase-ii-iii-study-for-registration-in-stroke-press-release https://www.acticor-biotech.com/posts/acticor-biotech-retient-simbec-orion-pour-une-etude-clinique-actulabo-fr https://www.acticor-biotech.com/posts/acticor-biotech-se-renforce-cf-news-fr https://www.acticor-biotech.com/posts/acticor-biotech-signe-en-chine-un-contrat-de-licence-de-plus-de-60-m-eur-afp-fr https://www.acticor-biotech.com/posts/acticor-biotech-signe-en-chine-un-contrat-de-plus-de-60m-eur-le-figaro-fr https://www.acticor-biotech.com/posts/acticor-biotech-strenghtens-its-financial-structure https://www.acticor-biotech.com/posts/acticor-biotech-successfully-completes-a-capital-increase-for-a-total-gross-amount-of-12-2-million-euros-via-the-issuance-of-1-793-005-shares https://www.acticor-biotech.com/posts/acticor-biotech-veut-faire-passer-un-cap-a-la-lutte-contre-lavc-decideurs-magazine-fr https://www.acticor-biotech.com/posts/actimis-post-hoc-results-on-imaging-stroke-data-using-artificial-intelligence-reinforces-glenzocimab-mode-of-action-in-stroke-patients https://www.acticor-biotech.com/posts/american-heart-association-experimental-antiplatelet-compound-for-acute-stroke-shows-promise https://www.acticor-biotech.com/posts/american-heart-association-new-drug-to-prevent-clots-clears-safety-hurdle https://www.acticor-biotech.com/posts/appointement-of-sophie-binay-general-manger-and-cso-to-the-board-of-directors-of-france-biotech https://www.acticor-biotech.com/posts/availability-of-the-2022-universal-registration-document-and-the-preparatory-documents-for-the-combined-general-meeting-of-may-12-2023 https://www.acticor-biotech.com/posts/avc-acticor-cible-plus-de-20-meu-capitalfinance-fr https://www.acticor-biotech.com/posts/avc-des-innovations-pour-gagner-quelques-precieuses-heures-lusine-nouvelle-fr https://www.acticor-biotech.com/posts/avc-les-promesses-de-la-science-lexpress-fr https://www.acticor-biotech.com/posts/ca-bouge-sur-les-marches-acticor-biotech-sintroduit-sur-euronext-growth-boursorama-fr https://www.acticor-biotech.com/posts/entretien-avec-gilles-avenard-dans-le-journal-des-biotechs-presente-par-laurent-grassin https://www.acticor-biotech.com/posts/fiercebiotech-acticors-blood-thinner-cuts-hemorrhage-risk-in-human-study-could-offer-hope-for-acute-stroke https://www.acticor-biotech.com/posts/gilles-avenard-recoit-le-prix-de-linnovation-2017-biotech-finances-fr https://www.acticor-biotech.com/posts/gordon-research-conference-cell-biology-of-megakaryocytes-and-platelets https://www.acticor-biotech.com/posts/healio-new-antiplatelet-may-lower-bleeding-risk-in-stroke https://www.acticor-biotech.com/posts/interview-gilles-avenard-revient-sur-les-resultats-positifs-dactimis-sur-boursorama-fr https://www.acticor-biotech.com/posts/interview-of-gilles-avenard-in-biotech-finances https://www.acticor-biotech.com/posts/introduction-en-bourse-d-acticor-biotech-interview-du-directeur-general-biotech-bourse-fr https://www.acticor-biotech.com/posts/iqvia-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/posts/isth-2019-congress-in-melbourne-australia https://www.acticor-biotech.com/posts/isth-honors-five-members-with-esteemed-career-awards https://www.acticor-biotech.com/posts/la-revue-du-praticien-avc-un-candidat-medicament https://www.acticor-biotech.com/posts/le-francais-acticor-biotech-signe-un-accord-de-developpement-en-chine-la-tribune-fr https://www.acticor-biotech.com/posts/le-quotidien-du-pharmacien-un-nouvel-antithrombotique-en-developpement https://www.acticor-biotech.com/posts/les-echos-la-start-up-acticor-qui-developpe-un-traitement-contre-les-avc-a-boucle-une-levee-de-fonds-en-serie-b-de-15-3-millions-deuros https://www.acticor-biotech.com/posts/les-entrepreneurs-de-la-healthtech-francaise-en-premiere-ligne-pour-lutter-contre-la-covid-19 https://www.acticor-biotech.com/posts/mcdermott-accompagne-acticor-biotech-le-monde-du-droit-fr https://www.acticor-biotech.com/posts/meet-us-at-biojapan-2019-with-gilles-avenard-ceo-of-acticor-biotech https://www.acticor-biotech.com/posts/newsmax-health-experimental-drug-can-prevent-strokes https://www.acticor-biotech.com/posts/participation-of-acticor-biotech-in-esoc-2023-first-european-forum-for-stroke-research-press-release https://www.acticor-biotech.com/posts/pharmacie-la-chine-seveille-le-figaro https://www.acticor-biotech.com/posts/report-of-the-combined-general-meeting-of-may-12-2023 https://www.acticor-biotech.com/posts/retrouvez-linterview-de-gilles-avenard-ceo-dacticor-biotech-sur-le-plateau-du-journal-des-biotechs-presente-par-laurent-grassin-fr https://www.acticor-biotech.com/posts/science-daily-experimental-antiplatelet-compound-for-acute-stroke-shows-promise https://www.acticor-biotech.com/posts/spring-midcap-event-meet-acticor-biotech-at-the-spring-midcap-event-in-paris https://www.acticor-biotech.com/posts/the-uk-regulatory-agency-mhra-approved-the-protocol-of-liberate-study-the-first-clinical-trial-evaluating-glenzocimab-for-heart-attacks https://www.acticor-biotech.com/posts/top-100-startups-to-invest-in-challenges-magazine https://www.acticor-biotech.com/posts/traiter-lavc-dans-lurgence-vers-de-strategies-therapeutiques-innovantes-connected-mag https://www.acticor-biotech.com/posts/un-nouvel-antithrombotique-fait-ses-premiers-pas-dans-lavc-le-quotidien-du-medecin-fr https://www.acticor-biotech.com/posts/update-on-acticor-biotechs-clinical-developments-with-glenzocimab-in-the-treatment-of-cardiovascular-emergencies https://www.acticor-biotech.com/posts/upi-new-blood-thinner-may-prevent-stroke-without-risk-for-bleeding https://www.acticor-biotech.com/posts/wheatfield-pediatrics-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/posts/worlds-first-clinical-trial-to-test-new-drug-glenzocimab-for-heart-attacks https://www.acticor-biotech.com/posts/yannick-pletan-est-nomme-directeur-medical-executives-fr https://www.acticor-biotech.com/posts/yannick-pletan-est-nomme-directeur-medical-responsable-de-la-r-d-clinique-et-des-affaires-medicales-les-echos-fr https://www.acticor-biotech.com/protected-page-demo https://www.acticor-biotech.com/quality-and-cost-assessment-of-a-recombinant-antibody-fragment-produced-from-mammalian-yeast-and-prokaryotic-host-cells-a-case-study-prior-to-pharmaceutical-development https://www.acticor-biotech.com/safety-and-tolerability-pharmacokinetics-and-pharmacodynamics-of-act017-an-antiplatelet-gpvi-glycoprotein-vi-fab https://www.acticor-biotech.com/spanish-biotech-clears-e2-7m-funding-round-for-its-new-stroke-drug-labiotech-eu https://www.acticor-biotech.com/stroke-company-acticor-biotech-and-mediolanum-announce-a-research-collaboration-agreement https://www.acticor-biotech.com/technologie https://www.acticor-biotech.com/technology https://www.acticor-biotech.com/the-journal-of-pharmacology-and-experimental-therapeutics-a-humanized-glycoprotein-vi-gpvi-mouse-model-to-assess-the-antithrombotic-efficacies-of-anti-gpvi-agents https://www.acticor-biotech.com/top-100-startups-to-invest-in-challenges-magazine https://www.acticor-biotech.com/top-100-startups-to-invest-in-challenges-magazine-2 https://www.acticor-biotech.com/top-20-start-up-sante-innovation-review https://www.acticor-biotech.com/traitement-des-avc-les-promesses-de-la-science-lexpress https://www.acticor-biotech.com/traiter-lavc-dans-lurgence-vers-de-strategies-therapeutiques-innovantes-connected-mag https://www.acticor-biotech.com/un-nouvel-antithrombotique-en-developpement-le-quotidien-du-pharmacien-fr https://www.acticor-biotech.com/un-nouvel-antithrombotique-fait-ses-premiers-pas-dans-lavc-le-quotidien-du-medecin-fr https://www.acticor-biotech.com/understanding-stroke https://www.acticor-biotech.com/understanding-stroke/a-new-target https://www.acticor-biotech.com/understanding-stroke/stroke-in-brief https://www.acticor-biotech.com/understanding-stroke/stroke-outcomes https://www.acticor-biotech.com/understanding-stroke/stroke-treatment https://www.acticor-biotech.com/yannick-pletan-est-nomme-directeur-medical-executives-fr https://www.acticor-biotech.com/yannick-pletan-est-nomme-directeur-medical-responsable-de-la-rd-clinique-et-des-affaires-medicales-les-echos-fr https://www.acticor-biotech.com/actisave-sub/index https://www.acticor-biotech.com/fr-sub/index https://www.acticor-biotech.com/fr-sub/about-stroke/about-stroke https://www.acticor-biotech.com/fr-sub/about-stroke/stroke-key-figures https://www.acticor-biotech.com/fr-sub/about-stroke/what-is-a-stroke https://www.acticor-biotech.com/fr-sub/articles-category/events https://www.acticor-biotech.com/fr-sub/articles-category/events_b460e1fd_page-1 https://www.acticor-biotech.com/fr-sub/articles-category/events_b460e1fd_page-2 https://www.acticor-biotech.com/fr-sub/articles-category/events_b460e1fd_page-3 https://www.acticor-biotech.com/fr-sub/articles-category/events_b460e1fd_page-4 https://www.acticor-biotech.com/fr-sub/articles-category/events_b460e1fd_page-5 https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage_b460e1fd_page-1 https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage_b460e1fd_page-2 https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage_b460e1fd_page-3 https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage_b460e1fd_page-4 https://www.acticor-biotech.com/fr-sub/articles-category/media-coverage_b460e1fd_page-5 https://www.acticor-biotech.com/fr-sub/articles-category/press-release https://www.acticor-biotech.com/fr-sub/articles-category/press-release_b460e1fd_page-1 https://www.acticor-biotech.com/fr-sub/articles-category/press-release_b460e1fd_page-2 https://www.acticor-biotech.com/fr-sub/articles-category/press-release_b460e1fd_page-3 https://www.acticor-biotech.com/fr-sub/articles-category/press-release_b460e1fd_page-4 https://www.acticor-biotech.com/fr-sub/articles-category/publications https://www.acticor-biotech.com/fr-sub/articles-category/publications_b460e1fd_page-1 https://www.acticor-biotech.com/fr-sub/articles-category/publications_b460e1fd_page-2 https://www.acticor-biotech.com/fr-sub/careers https://www.acticor-biotech.com/fr-sub/company/about-us https://www.acticor-biotech.com/fr-sub/company/board-of-directors https://www.acticor-biotech.com/fr-sub/company/partners https://www.acticor-biotech.com/fr-sub/company/prizes https://www.acticor-biotech.com/fr-sub/company/team https://www.acticor-biotech.com/fr-sub/contact-acticor-biotech https://www.acticor-biotech.com/fr-sub/events https://www.acticor-biotech.com/fr-sub/investors/ask-us-your-question https://www.acticor-biotech.com/fr-sub/investors/contact https://www.acticor-biotech.com/fr-sub/investors/corporate-presentation https://www.acticor-biotech.com/fr-sub/investors/financial-agenda https://www.acticor-biotech.com/fr-sub/investors/investors-home https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/financial-information-2021 https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/financial-information-2022 https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/governance https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/other-regulated-information https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/other-regulated-information-2021 https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/other-regulated-information-2023 https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/regulated-information https://www.acticor-biotech.com/fr-sub/investors/regulated-information-2/shareholders-meeting https://www.acticor-biotech.com/fr-sub/investors/share-overview https://www.acticor-biotech.com/fr-sub/investors/subscribe-to-email-alert https://www.acticor-biotech.com/fr-sub/legal-mentions https://www.acticor-biotech.com/fr-sub/media-coverage https://www.acticor-biotech.com/fr-sub/our-product/actimis-study-positive-results https://www.acticor-biotech.com/fr-sub/our-product/glenzocimab-in-acute-ischemic-stroke https://www.acticor-biotech.com/fr-sub/our-product/glenzocimab-in-other-indications https://www.acticor-biotech.com/fr-sub/our-product/glenzocimab-in-stemi https://www.acticor-biotech.com/fr-sub/our-product/gpvi-glenzocimab-in-brief https://www.acticor-biotech.com/fr-sub/our-product/our-product-glenzocimab https://www.acticor-biotech.com/fr-sub/pipeline https://www.acticor-biotech.com/fr-sub/posts/10-meu-cest-le-montant-de-la-levee-de-fonds-pour-acticor-biotech-biotech-finances-fr https://www.acticor-biotech.com/fr-sub/posts/2021-full-year-financial-results-and-update-on-clinical-development https://www.acticor-biotech.com/fr-sub/posts/24emes-journees-de-la-societe-francaise-neuro-vasculaire https://www.acticor-biotech.com/fr-sub/posts/a-60meu-regional-development-and-commercialisation-agreement-signed-with-china-medical-system-holding-limited-r https://www.acticor-biotech.com/fr-sub/posts/act017-un-fragment-danticorps-dont-laction-antithrombotique-est-prometteuse https://www.acticor-biotech.com/fr-sub/posts/acticor-15-meu-pour-devenir-premier-de-la-classe-biotech-finances-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-adapts-its-actisave-clinical-study-to-prepare-the-registration-of-glenzocimab-for-the-treatment-of-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-a-recu-le-prix-de-linnovation-2017-caduresco-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-avec-son-candidat-act017-industrie-mag-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-annonce-la-fin-de-son-etude-clinique-de-phase-i-biotech-finance-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-appointment-of-dr-yannick-pletan-as-chief-medical-officer-biotech-finances https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-appointment-of-mr-alain-munoz-as-chairman-of-the-board-of-directors-and-mrs-sophie-binay-and-mr-yannick-pletan-as-general-managers https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-coverage-of-its-stock-by-gilbert-dupont-and-kepler-cheuvreux https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-fda-acceptance-of-ind-application-for-glenzocimab-in-acute-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-its-2022-half-year-financial-results-and-update-on-its-clinical-progress https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-its-financial-agenda-for-the-1st-half-of-2023 https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-its-projected-ipo-on-the-euronext-growth-r-market-in-paris https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-positive-results-from-its-actimis-phase-1b-2a-study-in-patients-with-acute-ischemic-stroke-ais https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-that-the-european-medicines-agency-clears-the-route-for-a-phase-ii-of-its-act017-product-in-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-appointment-of-corinne-le-goff-to-the-board-of-directors-as-an-independent-director https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-appointment-of-patricia-zilliox-to-the-board-of-directors-as-an-independent-director https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-closing-of-a-eu1-7-million-equity-financing-led-by-primer-capital https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-completion-of-enrollment-in-actimis-its-key-phase-1b-2a-safety-study https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-completion-of-enrollment-in-its-garden-clinical-trial-a-covid-19-induced-acute-respiratory-distress-syndrome-efficacy-study https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-enrollment-of-the-first-us-patient-in-its-phase-2-3-study-actisave-for-the-treatment-of-stroke-press-release https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-first-patient-in-actisave-its-adaptive-phase-2-3-efficacy-study-in-acute-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-issuance-of-a-patent-in-europe-for-glenzocimab-its-innovative-product-for-the-treatment-of-cardiovascular-emergencies https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-recruitment-of-the-first-patient-in-its-phase-2-garden-study-in-covid-19-related-ards https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-announces-the-success-of-the-first-phase-of-its-actimis-study-with-glenzocimab-in-patients-with-acute-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-augmenter-les-chances-de-survie-dans-lavc-investir-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-completed-its-phase-i-clinical-trial-with-act017-achieving-its-safety-and-tolerability-primary-endpoints https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-confirms-simbec-orion-to-make-its-first-in-patient-study-in-acute-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-first-in-human-clinical-trial-in-healthy-volunteers https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-has-selected-its-contract-research-organisation-to-manage-clinical-study-phase-i https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-integre-le-1-er-french-tech-120 https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-internationalise-son-tour-de-table-les-echos-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-introduction-en-bourse-et-levee-de-fonds-de-20meu-lancees https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-is-nominated-for-the-8th-edition-of-the-galien-medstartup-awards-october-27-28-2021-in-new-york-city https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-is-the-laureate-of-the-prix-galien-medstartup-award-in-the-category-best-collaboration-in-the-pharmaceutical-or-biotechnology-industry https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-karista-the-rise-of-a-game-changer-to-fight-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-launches-a-capital-increase-for-an-amount-of-c-10-million-euros https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-launches-its-initial-public-offering-on-the-euronext-growth-r-market-in-paris https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-obtains-prime-status-from-the-european-medicines-agency-for-glenzocimab-in-the-treatment-of-stroke https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-partner-of-the-booster-consortium-dedicated-to-management-and-new-treatments-of-stroke-in-emergency-situations https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-postpones-release-of-its-2022-half-year-financial-results https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-progress-in-discussions-with-eu-and-us-regulatory-agencies https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-provides-an-update-on-the-us-regulatory-discussion-with-the-fda https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-publishes-its-2022-annual-results-and-provides-an-update-on-its-clinical-progress https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-raises-eu7m-in-addition-to-its-series-b-financing-now-completed-at-eu22-3m https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-realise-une-augmentation-de-capital-de-1-7meu-biotech-info-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-receives-european-medicines-agency-ema-endorsement-on-key-parameters-of-actisave-its-pivotal-phase-ii-iii-study-for-registration-in-stroke-press-release https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-retient-simbec-orion-pour-une-etude-clinique-actulabo-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-se-renforce-cf-news-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-signe-en-chine-un-contrat-de-licence-de-plus-de-60-m-eur-afp-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-signe-en-chine-un-contrat-de-plus-de-60m-eur-le-figaro-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-strenghtens-its-financial-structure https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-successfully-completes-a-capital-increase-for-a-total-gross-amount-of-12-2-million-euros-via-the-issuance-of-1-793-005-shares https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-veut-faire-passer-un-cap-a-la-lutte-contre-lavc-decideurs-magazine-fr https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-wishes-you-a-happy-new-year https://www.acticor-biotech.com/fr-sub/posts/acticor-biotech-wishes-you-a-happy-new-year-2 https://www.acticor-biotech.com/fr-sub/posts/acticor-reached-the-milestones-triggering-the-second-payment-in-the-research-agreement-with-its-pharma-partner-mediolanum https://www.acticor-biotech.com/fr-sub/posts/acticor-releve-7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/fr-sub/posts/actimis-post-hoc-results-on-imaging-stroke-data-using-artificial-intelligence-reinforces-glenzocimab-mode-of-action-in-stroke-patients https://www.acticor-biotech.com/fr-sub/posts/acute-ischemic-stroke-thrombi-have-an-outer-shell-that-impairs-fibrinolysis https://www.acticor-biotech.com/fr-sub/posts/american-heart-association-experimental-antiplatelet-compound-for-acute-stroke-shows-promise https://www.acticor-biotech.com/fr-sub/posts/american-heart-association-new-drug-to-prevent-clots-clears-safety-hurdle https://www.acticor-biotech.com/fr-sub/posts/american-heart-association-new-drug-to-prevent-clots-clears-safety-hurdle-2 https://www.acticor-biotech.com/fr-sub/posts/appointement-of-sophie-binay-general-manger-and-cso-to-the-board-of-directors-of-france-biotech https://www.acticor-biotech.com/fr-sub/posts/availability-of-the-2021-universal-registration-document-and-the-preparatory-documents-for-the-combined-general-meeting-of-may-12-2022 https://www.acticor-biotech.com/fr-sub/posts/availability-of-the-2022-universal-registration-document-and-the-preparatory-documents-for-the-combined-general-meeting-of-may-12-2023 https://www.acticor-biotech.com/fr-sub/posts/avc-acticor-cible-plus-de-20-meu-capitalfinance-fr https://www.acticor-biotech.com/fr-sub/posts/avc-des-innovations-pour-gagner-quelques-precieuses-heures-lusine-nouvelle-fr https://www.acticor-biotech.com/fr-sub/posts/avc-les-promesses-de-la-science-lexpress-fr https://www.acticor-biotech.com/fr-sub/posts/bio-2023-meet-acticor-biotech-at-the-next-bio-conference-in-boston-united-states https://www.acticor-biotech.com/fr-sub/posts/bio-equity-2023-meet-acticor-biotech-at-the-next-bio-equity-in-dublin-ireland https://www.acticor-biotech.com/fr-sub/posts/bio-equity-meet-acticor-biotech-at-bio-equity-in-milan https://www.acticor-biotech.com/fr-sub/posts/bio-europe-leipzig-oct-24-26-2022-meet-acticor-biotech-at-bio-europe-in-leipzig https://www.acticor-biotech.com/fr-sub/posts/bio-europe-spring-2022-meet-acticor-biotech-at-bio-europe-spring-in-basel https://www.acticor-biotech.com/fr-sub/posts/bio-san-diego https://www.acticor-biotech.com/fr-sub/posts/bio-spring-2023-meet-acticor-biotech-at-the-next-bio-spring-conference-in-basel-switzerland https://www.acticor-biotech.com/fr-sub/posts/biotech-info-acticor-biotech-partenaire-du-consortium-booster-dedie-a-la-prise-en-charge-et-aux-nouveaux-traitements-des-avc https://www.acticor-biotech.com/fr-sub/posts/blood-journal-platelet-glycoprotein-vi-binds-to-polymerized-fibrin-and-promotes-thrombin-generation https://www.acticor-biotech.com/fr-sub/posts/ca-bouge-sur-les-marches-acticor-biotech-sintroduit-sur-euronext-growth-boursorama-fr https://www.acticor-biotech.com/fr-sub/posts/capitalfinance-acticor-biotech-porte-sa-serie-b-a-22-3-meu https://www.acticor-biotech.com/fr-sub/posts/cardiologyconsultant-novel-antiplatelet-may-offer-antithrombotic-effect-without-bleeding-risk https://www.acticor-biotech.com/fr-sub/posts/cardiovascularbusiness-novel-antiplatelet-could-circumvent-bleeding-risk-for-stroke-patients https://www.acticor-biotech.com/fr-sub/posts/design-development-and-characterization-of-act017-a-humanized-fab-that-blocks-platelets-glycoprotein-vi-function-without-causing-bleeding-risks https://www.acticor-biotech.com/fr-sub/posts/dia-europe-2023-meet-acticor-biotech-at-the-next-dia-europe-in-basel-switzerland https://www.acticor-biotech.com/fr-sub/posts/entretien-avec-gilles-avenard-dans-le-journal-des-biotechs-presente-par-laurent-grassin https://www.acticor-biotech.com/fr-sub/posts/esc-2023-meet-acticor-biotech-at-the-next-esc-conference-in-amsterdam-netherlands https://www.acticor-biotech.com/fr-sub/posts/esoc-2023-meet-acticor-biotech-at-the-next-european-stroke-conference-in-munich-germany https://www.acticor-biotech.com/fr-sub/posts/esoc22-meet-acticor-biotech-at-the-8th-european-stroke-organisation-conference https://www.acticor-biotech.com/fr-sub/posts/fiercebiotech-acticors-blood-thinner-cuts-hemorrhage-risk-in-human-study-could-offer-hope-for-acute-stroke https://www.acticor-biotech.com/fr-sub/files/-phase-1b-2a-actimis-chez-les-patients-atteints-daccident-vasculaire-cerebral-avc-ischemique-retrouvez-les-slides-de-presentation-du-webinaire_hrebbdkpbsn05xijqdq67r https://www.acticor-biotech.com/fr-sub/posts/gilles-avenard-recoit-le-prix-de-linnovation-2017-biotech-finances-fr https://www.acticor-biotech.com/fr-sub/posts/glenzocimab-does-not-impact-glycoprotein-vi-dependent-inflammatory-haemostasis https://www.acticor-biotech.com/fr-sub/posts/gordon-research-conference-cell-biology-of-megakaryocytes-and-platelets https://www.acticor-biotech.com/fr-sub/posts/healio-new-antiplatelet-may-lower-bleeding-risk-in-stroke https://www.acticor-biotech.com/fr-sub/posts/immobilized-fibrinogen-activates-human-platelets-through-glycoprotein-vi https://www.acticor-biotech.com/fr-sub/posts/international-journal-of-stroke-beyond-antiplatelets-the-role-of-glycoprotein-vi-in-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/interview-de-franck-mouthon-president-de-france-biotech-sur-les-societes-de-sante-ayant-integre-la-french-tech-120-sur-bfm-business https://www.acticor-biotech.com/fr-sub/posts/interview-gilles-avenard-revient-sur-les-resultats-positifs-dactimis-sur-boursorama-fr https://www.acticor-biotech.com/fr-sub/posts/interview-of-gilles-avenard-in-biotech-finances https://www.acticor-biotech.com/fr-sub/posts/introduction-en-bourse-d-acticor-biotech-interview-du-directeur-general-biotech-bourse-fr https://www.acticor-biotech.com/fr-sub/posts/investir-day-meet-acticor-biotech-at-investir-day-forum-palais-brongniart-paris https://www.acticor-biotech.com/fr-sub/posts/investor-access-oct-6-7-2022-meet-acticor-biotech-at-the-next-investor-access https://www.acticor-biotech.com/fr-sub/posts/iqvia-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/fr-sub/posts/isc-2022 https://www.acticor-biotech.com/fr-sub/posts/isc-2023-meet-acticor-biotech-at-the-next-international-stroke-conference-in-dallas-united-states https://www.acticor-biotech.com/fr-sub/posts/isfp-2022 https://www.acticor-biotech.com/fr-sub/posts/isth-2019-congress-in-melbourne-australia https://www.acticor-biotech.com/fr-sub/posts/isth-2022 https://www.acticor-biotech.com/fr-sub/posts/isth-honors-five-members-with-esteemed-career-awards https://www.acticor-biotech.com/fr-sub/posts/journal-of-thrombosis-and-haemostasis-antiplatelet-drugs-which-targets-for-which-treatments https://www.acticor-biotech.com/fr-sub/posts/jpet-a-humanized-glycoprotein-vi-gpvi-mouse-model-to-assess-the-antithrombotic-efficacies-of-anti-gpvi-agents https://www.acticor-biotech.com/fr-sub/posts/la-revue-du-praticien-avc-un-candidat-medicament https://www.acticor-biotech.com/fr-sub/posts/le-francais-acticor-biotech-signe-un-accord-de-developpement-en-chine-la-tribune-fr https://www.acticor-biotech.com/fr-sub/posts/le-quotidien-du-pharmacien-un-nouvel-antithrombotique-en-developpement https://www.acticor-biotech.com/fr-sub/posts/les-echos-7-millions-pour-sattaquer-a-lavc-ischemique-aigu https://www.acticor-biotech.com/fr-sub/posts/les-echos-la-start-up-acticor-qui-developpe-un-traitement-contre-les-avc-a-boucle-une-levee-de-fonds-en-serie-b-de-15-3-millions-deuros https://www.acticor-biotech.com/fr-sub/posts/les-entrepreneurs-de-la-healthtech-francaise-en-premiere-ligne-pour-lutter-contre-la-covid-19 https://www.acticor-biotech.com/fr-sub/posts/mcdermott-accompagne-acticor-biotech-le-monde-du-droit-fr https://www.acticor-biotech.com/fr-sub/posts/medintechs-come-meet-acticor-biotech-at-the-medintechs-event-in-paris https://www.acticor-biotech.com/fr-sub/posts/meet-acticor-biotech-at-biofit-conference https://www.acticor-biotech.com/fr-sub/posts/meet-acticor-biotech-at-biotech-show-case-san-fransico-usa https://www.acticor-biotech.com/fr-sub/posts/meet-acticor-biotech-at-the-next-biotech-showcase-conference-in-san-francisco https://www.acticor-biotech.com/fr-sub/posts/meet-us-at-bio-europe-2019 https://www.acticor-biotech.com/fr-sub/posts/meet-us-at-biojapan-2019-with-gilles-avenard-ceo-of-acticor-biotech https://www.acticor-biotech.com/fr-sub/posts/meet-us-at-biotech-showcase-san-fransisco-ca-jan-13-15-202 https://www.acticor-biotech.com/fr-sub/posts/midcap-event-paris https://www.acticor-biotech.com/fr-sub/posts/newsmax-health-experimental-drug-can-prevent-strokes https://www.acticor-biotech.com/fr-sub/posts/paris-biotech-sante https://www.acticor-biotech.com/fr-sub/posts/participation-of-acticor-biotech-in-esoc-2023-first-european-forum-for-stroke-research-press-release https://www.acticor-biotech.com/fr-sub/posts/penn-state-health-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/fr-sub/posts/pharmacie-la-chine-seveille-le-figaro https://www.acticor-biotech.com/fr-sub/posts/pharmacological-blockade-of-glycoprotein-vi-promotes-thrombus-disaggregation-in-the-absence-of-thrombin https://www.acticor-biotech.com/fr-sub/posts/platelets-drive-thrombus-propagation-in-a-hematocrit-and-glycoprotein-vi-dependent-manner-in-an-in-vitro-venous-thrombosis-model https://www.acticor-biotech.com/fr-sub/posts/population-pharmacokinetic-pharmacodynamic-modeling-of-glenzocimab-act017-a-glycoprotein-vi-inhibitor-of-collagen-induced-platelet-aggregation https://www.acticor-biotech.com/fr-sub/posts/presentation-of-positive-results-from-the-actimis-phase-1b-2a-study-in-stroke-at-esoc-2022 https://www.acticor-biotech.com/fr-sub/posts/quality-and-cost-assessment-of-a-recombinant-antibody-fragment-produced-from-mammalian-yeast-and-prokaryotic-host-cells-a-case-study-prior-to-pharmaceutical-development https://www.acticor-biotech.com/fr-sub/posts/report-of-the-combined-general-meeting-of-may-12-2023 https://www.acticor-biotech.com/fr-sub/posts/results-of-the-phase-2-garden-study-in-covid-19-related-acute-respiratory-distress-syndrome-and-exclusive-interview-with-acticor-biotech-management https://www.acticor-biotech.com/fr-sub/posts/retrouvez-linterview-de-gilles-avenard-ceo-dacticor-biotech-sur-le-plateau-du-journal-des-biotechs-presente-par-laurent-grassin-fr https://www.acticor-biotech.com/fr-sub/posts/safety-and-tolerability-pharmacokinetics-and-pharmacodynamics-of-act017-an-antiplatelet-gpvi-glycoprotein-vi-fab https://www.acticor-biotech.com/fr-sub/posts/science-daily-experimental-antiplatelet-compound-for-acute-stroke-shows-promise https://www.acticor-biotech.com/fr-sub/posts/sfnv-22 https://www.acticor-biotech.com/fr-sub/posts/sfnv-meet-acticor-biotech-at-the-26th-societe-francaise-de-neuro-vasculaire-days https://www.acticor-biotech.com/fr-sub/posts/small-cap-event-meet-acticor-biotech-at-the-small-cap-event-in-paris https://www.acticor-biotech.com/fr-sub/posts/spring-midcap-event-paris https://www.acticor-biotech.com/fr-sub/posts/success-of-acticor-biotechs-initial-public-offering-on-the-euronext-growth-r-market-with-eu15-5-million-raised https://www.acticor-biotech.com/fr-sub/posts/svin-meet-acticor-biotech-at-the-society-of-vascular-and-interventional-neurology-annual-meeting-phoenix-usa https://www.acticor-biotech.com/fr-sub/posts/svin-meeting https://www.acticor-biotech.com/fr-sub/posts/targeting-platelet-gpvi-with-glenzocimab-a-novel-mechanism-for-inhibition-blood-advances https://www.acticor-biotech.com/fr-sub/posts/the-uk-regulatory-agency-mhra-approved-the-protocol-of-liberate-study-the-first-clinical-trial-evaluating-glenzocimab-for-heart-attacks https://www.acticor-biotech.com/fr-sub/posts/top-100-startups-to-invest-in-challenges-magazine https://www.acticor-biotech.com/fr-sub/posts/traiter-lavc-dans-lurgence-vers-de-strategies-therapeutiques-innovantes-connected-mag https://www.acticor-biotech.com/fr-sub/posts/un-nouvel-antithrombotique-fait-ses-premiers-pas-dans-lavc-le-quotidien-du-medecin-fr https://www.acticor-biotech.com/fr-sub/posts/update-on-acticor-biotechs-clinical-developments-with-glenzocimab-in-the-treatment-of-cardiovascular-emergencies https://www.acticor-biotech.com/fr-sub/posts/upi-new-blood-thinner-may-prevent-stroke-without-risk-for-bleeding https://www.acticor-biotech.com/fr-sub/posts/webinar-presenting-positive-results-from-its-phase-1b-2a-study-actimis-in-patients-with-ischemic-stroke https://www.acticor-biotech.com/fr-sub/posts/wheatfield-pediatrics-experimental-blood-thinner-may-help-prevent-stroke-without-the-bleeding-risk https://www.acticor-biotech.com/fr-sub/posts/wlnc-2023-meet-acticor-biotech-at-the-next-wlnc-conference-in-rio-brasil https://www.acticor-biotech.com/fr-sub/posts/world-stroke-day-2021 https://www.acticor-biotech.com/fr-sub/posts/worlds-first-clinical-trial-to-test-new-drug-glenzocimab-for-heart-attacks https://www.acticor-biotech.com/fr-sub/posts/wsc-2023-meet-acticor-biotech-at-the-15th-world-stroke-congress-in-toronto-canada https://www.acticor-biotech.com/fr-sub/posts/wsc-22 https://www.acticor-biotech.com/fr-sub/posts/yannick-pletan-est-nomme-directeur-medical-executives-fr https://www.acticor-biotech.com/fr-sub/posts/yannick-pletan-est-nomme-directeur-medical-responsable-de-la-r-d-clinique-et-des-affaires-medicales-les-echos-fr https://www.acticor-biotech.com/fr-sub/press-releases https://www.acticor-biotech.com/fr-sub/publications https://www.acticor-biotech.com/preprod-actisave-sub/index https://www.acticor-biotech.com/viya-sub/SASLogon/login